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and protein aggregates that have the poten-
tial to cause or exacerbate cell injury. This 
could be particularly important for dam-
aged mitochondria, which have a decreased 
ability to produce ATP and an increased 
potential for producing toxic reactive oxy-
gen species. Another important organelle 
that may be targeted for turnover through 
autophagy is the peroxisome. Peroxisomes 
are organelles that function in lipid metab-
olism and breakdown of hydrogen peroxide 
and are ‘marked’ for turnover when they 
are in excess or damaged. The role played 
by autophagy in promoting cell survival 
by preventing the accumulation of aged or 
damaged cytosolic organelles and macro-
molecules still needs to be determined by 
additional research.
In summary, autophagy has entered the 
research spotlight during the past few years 
because of the discovery of mammalian 
orthologues of yeast autophagy genes and 
the elucidation of the mechanisms involved 
in the autophagic cycle (Figure 1). These 
studies have revealed the highly conserved 
nature of autophagy and have implicated 
autophagy pathogenesis of a wide array of 
disease states. The study by Periyasamy-
Thandavan et al.13 highlights the potential 
role of autophagy as a survival mechanism 
following cytotoxic injury to the kidney and 
is also relevant to the potential protective 
role of autophagy in acute injury to other 
organs, such as brain, heart, and liver.6,11
As our understanding of the mecha-
nisms involved in autophagy continues to 
evolve, it is likely that specific pharmaco-
logic agents will become available that can 
enhance or inhibit autophagic activity.14 
These agents could prove useful for the 
treatment of diseases in which autophagy 
plays an important role.14 However, a great 
deal of additional research is necessary in 
order to define the role of autophagy in 
the pathogenesis of different disease states 
before we are able to determine the thera-
peutic utility of pharmacologic agents that 
modulate the autophagic cycle.
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Once-yearly intravenous 
zoledronate does not impair  
renal function in  
postmenopausal women
Marie-Hélène Lafage-Proust1
Zoledronate, a potent third-generation amino-bisphosphonate 
previously used for the treatment of bone metastasis, was recently 
shown to significantly reduce the risk of vertebral and hip fractures in 
osteoporotic postmenopausal women when infused at a dose of  
5 mg per year for 3 years. The renal follow-up of this pivotal study that 
included more than 5,000 patients (estimated creatinine clearance  
>30 ml per min) is reported by Boonen et al. and shows the long-term 
renal safety of zoledronate in this osteoporotic population.
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Bisphosphonates, potent inhibitors of 
osteoclastic resorption, are bone-seeking 
drugs with very high affinity for mineral-
ized collagen matrix. Therefore, they are 
cleared rapidly from the circulation, with 
about half the administered dose taken 
up by the skeleton while the other half is 
excreted, unmetabolized, by the kidneys.1 
After being embedded in bone at the 
remodeling sites,2 they are slowly released 
from bone into the circulation,3 when a 
remodeling cycle is again initiated at the 
bone surface. Therefore, because bisphos-
phonates remain in bone for years when 
administered daily, the idea of exploiting 
the considerable skeletal persistence of 
these drugs was raised, and bisphospho-
nates were then given weekly, and after 
that monthly, and are now proposed to 
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be administered once a year. The other 
rationales for using yearly intravenous 
treatment for osteoporosis were that 
many studies showed that poor patient 
compliance with oral bisphosphonates 
highly compromised the reduction of 
fracture risk,4 and that bisphosphonates 
have very low oral bioavailability and can 
cause esophageal irritation (Figure 1). 
Zoledronate is a third-generation het-
erocyclic amino-bisphosphonate, first 
used for sequential intravenous treat-
ment of malignant hypercalcemia, bone 
metastasis, and myeloma, at high doses 
(more than 10 times the dose advised for 
postmenopausal osteoporosis). Special 
attention to potential renal zoledronate 
toxicity was drawn when cases of acute 
tubular necrosis after monthly infu-
sions of zoledronate5 were reported 
in six patients (including five patients 
with multiple myeloma and one with 
Paget’s disease of bone). However, when 
phase III controlled trials of zoledronic 
acid use in oncology patients were pub-
lished, no significant renal toxicity was 
observed, provided that only 4 mg per 
infusion was administered over a 15-min 
period6 and that it was not advised in 
patients with severely impaired renal 
function (creatinine clearance below 40 
ml per min).7 
In a ‘true-life’ retrospective study, 
McDermott et al.8 reported renal function 
follow-up for a total of 3,115 zoledronate 
doses administered to 446 cancer patients 
(range: 1–28 doses per patient; dose: 
4 mg per 3–4 weeks). Forty-two patients 
experienced renal deterioration, requir-
ing discontinuation of zoledronic acid 
therapy in eight cases. Predictive factors 
for the development of renal deteriora-
tion were patient age, myeloma or renal-
cell cancer, cumulative number of doses, 
concomitant therapy with a nonsteroidal 
anti-inflammatory drug, and current or 
prior therapy with cisplatin. 
Now, intravenous zoledronate is pro-
posed for the treatment of osteoporosis 
at the annual dose of 5 mg. In the HORI-
ZON Pivotal Fracture Trial study, Black 
et al.9 showed that three yearly infusions 
of zoledronate significantly reduced the 
risk of morphometric vertebral fracture 
by 70% and of hip fracture by 41% as 
compared with placebo. 
Boonen et al.10 (this issue) now report 
the renal-function survey of the HORI-
ZON Pivotal Fracture Trial in a cohort 
of 5,035 osteoporotic postmenopausal 
women. For short-term renal safety, 
serum creatinine and estimated clear-
ance were measured between 9 and 11 
days after each infusion, and for long-
term renal safety, these parameters were 
compared at 12, 24, and 36 months (pla-
cebo, n = 2,514; zoledronate, n = 2,521). 
Basically, the authors report a transient 
increase in serum creatinine over 5 mg/
dl in a higher number of patients under 
zoledronate than under placebo after 
the second infusion only (0.1% versus 
0.7%, P = 0.002). All patients recovered 
to within 0.5 mg/dl of their pre-infusion 
serum creatinine value within 12 months. 
Thus, these data show that if the serum 
creatinine level rises under zoledronate 
in a few patients, it resumes the baseline 
values after one year. The mean decrease 
in serum creatinine in these elderly 
patients was similar in both groups, as 
well as the overall number of observed 
renal adverse effects. Acute renal fail-
ure requiring hospitalization occurred 
in four patients under zoledronate 
(two had baseline creatinine clearance 
at 31 ml per min) and in three under 
placebo. These data are in line with 
other studies in humans. 
In 350 postmenopausal women 
under various doses and infusion 
regimens of zoledronic acid, Reid et 
al.11 did not observe any significant 
renal side effects. Recently, Lyles et 
al.12 reported a randomized, double-
blind, placebo-controlled trial in which 
patients after hip fracture were assigned 
to receive either yearly 5 mg intravenous 
zoledronic acid (n = 1,065) or placebo 
(n = 1,065). The authors showed that 
zoledronate reduced recurrent frac-
ture by 35% (P < 0.001) as compared 
with placebo. Interestingly, this study 
included men and women older than 
50 years (mean age 75 years) with a cre-
atinine clearance higher than 30 ml per 
min. The changes in serum creatinine 
levels or in estimated clearance were 
similar between the two groups. 
In conclusion, the study by Boonen 
et al.10 demonstrates that a 3-year 
treatment with yearly infusion of 5 mg 
zoledronate is safe for the kidneys in 
postmenopausal osteoporotic women 
with creatinine clearance above 30 ml 
per min. This efficient new pharmaco-
logical approach should help to improve 
compliance and adherence to treatments 
in this population. However, further 
studies are needed to assess the renal 
safety of zoledronate for longer periods 
of treatment.
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figure 1 | Comparison of bioavailability of bisphosphonates between oral and intravenous 
administration. (Adapted with permission from ref. 13.)
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